---
document_datetime: 2025-12-02 04:50:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/braftovi.html
document_name: braftovi.html
version: success
processing_time: 0.125906
conversion_datetime: 2025-12-24 05:37:07.249644
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Braftovi

[RSS](/en/individual-human-medicine.xml/66981)

##### Authorised

This medicine is authorised for use in the European Union

encorafenib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Braftovi](#news-on)
- [More information on Braftovi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Braftovi is a medicine used in adults for treating certain cancers when their cells have a mutation (change) in their genes called 'BRAF V600'.

Braftovi is used in combination with another medicine, binimetinib to treat:

- melanoma (a skin cancer) that cannot be removed by surgery or has spread;
- a type of lung cancer called non-small cell lung cancer (NSCLC). It is used when the cancer is advanced and has the BRAF V600E version of the mutation.

Braftovi is also used in combination with the medicine cetuximab to treat colorectal cancer (cancer of the large bowel or rectum) with the BRAF V600E version of the mutation, when it has spread elsewhere in the body and has previously been treated with other systemic (given by mouth or injection) medicines.

Braftovi contains the active substance encorafenib.

Expand section

Collapse section

## How is Braftovi used?

Braftovi can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in using cancer medicines.

The medicine is available as capsules taken by mouth once daily and the dose depends on the condition being treated. The dose may be reduced, or treatment may be stopped temporarily, if the patient experiences severe side effects. The dose of the other medicine, binimetinib or cetuximab, may also be reduced but if the other medicine is stopped Braftovi must be stopped too.

Treatment with Braftovi can last for as long as the patient benefits from it and does not have unacceptable side effects.

For more information about using Braftovi, see the package leaflet or contact your doctor or pharmacist.

## How does Braftovi work?

In cancers with a BRAF V600 mutation, an abnormal form of the protein BRAF is present, which switches on another protein called MEK involved in stimulating cell division. This encourages cancers to develop by allowing uncontrolled division of cells. The active substance in Braftovi, encorafenib, works by blocking the BRAF protein thereby stopping its activation of cell division and slowing down the growth and spread of the cancer.

## What benefits of Braftovi have been shown in studies?

**Melanoma**

A study of 577 patients with melanoma with a BRAF V600 mutation that had spread or could not be removed surgically showed that Braftovi with binimetinib can prolong the length of time patients lived without their disease getting worse.

Patients who took this combination lived on average for nearly 15 months without the disease getting worse. This compared with over 9.5 months for patients who took Braftovi alone and just over 7 months for patients taking a different medicine called vemurafenib.

**Colorectal cancer**

In a study involving 665 patients with previously treated colorectal cancer with the BRAF V600E mutation that had spread to other parts of the body, Braftovi with cetuximab improved response rates and prolonged the length of time that patients lived compared with treatment using cetuximab with other cancer medicines. Around 20% of patients given Braftovi with cetuximab responded to treatment, compared with about 2% in those not given Braftovi. The average length of time that patients given Braftovi and cetuximab lived was 9.3 months, compared with 5.9 months among those given other medicines.

**Non-small cell lung cancer**

The benefits of Braftovi given with binimetinib were evaluated in a main study involving 98 patients who had advanced NSCLC with the BRAF V600E mutation, which included patients who had not received prior treatment for NSCLC and those who had. The study did not compare the combination of Braftovi and binimetinib with other medicines or placebo (a dummy treatment). The main measure of effectiveness was the percentage of patients who responded to treatment, with either no sign of cancer or a decrease in the extent of the cancer after treatment. Around 75% of patients who had not received prior treatment responded to Braftovi given with binimetinib, and they lived for an average of 40 months without their cancer getting worse. Around 46% of patients who had received prior treatment responded to this combination, and they lived for an average of around 17 months without their cancer getting worse.

## What are the risks associated with Braftovi?

For the full list of side effects and restrictions, see the package leaflet.

The most common side effects (which can affect more than 1 in 4 people) with Braftovi and binimetinib taken together at the highest recommended doses include tiredness, nausea (feeling sick), diarrhoea, vomiting, abdominal (belly) pain, muscle pain or problems with the muscles, and joint pain

The most common side effects with Braftovi and cetuximab (which can affect more than 1 in 4 people) include tiredness, nausea (feeling sick), diarrhoea, dermatitis acneiform (a skin condition that causes small, raised, acne-like bumps to form, usually on the face, scalp, chest, and upper back), abdominal pain, joint pain or pain in the muscles and bones, decreased appetite, rash and vomiting.

## Why is Braftovi authorised in the EU?

Up to 50% of patients with metastatic melanoma have a mutation in the BRAF gene, with forms of the V600 mutation being the most common. Braftovi, in combination with binimetinib, can help prolong the time that these patients live without their cancer getting worse.

Although the study in patients with NSCLC did not directly compare Braftovi and binimetinib with any other treatment, the benefits in patients with advanced NSCLC with a BRAF V600E mutation who had not received prior treatment were similar to those seen with the current standard of care (treatment that medical experts consider most appropriate). While the treatment effect of this combination was lower in patients who had received previous treatment, it was still considered beneficial for these patients.

In patients with previously-treated colorectal cancer and a BRAF V600E mutation, Braftovi with cetuximab has been shown to produce a meaningful improvement in the length of time they live. The side effects seen with Braftovi are similar to those seen with other medicines in the same class and are considered manageable.

The European Medicines Agency therefore decided that Braftovi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Braftovi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Braftovi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Braftovi are continuously monitored. Side effects reported with Braftovi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Braftovi

Braftovi received a marketing authorisation valid throughout the EU on 20 September 2018.

Braftovi : EPAR - Medicine overview

Reference Number: EMA/372420/2024

English (EN) (149.09 KB - PDF)

**First published:** 12/10/2018

**Last updated:** 23/09/2024

[View](/en/documents/overview/braftovi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-264)

български (BG) (165.64 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/bg/documents/overview/braftovi-epar-medicine-overview_bg.pdf)

español (ES) (138.18 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/es/documents/overview/braftovi-epar-medicine-overview_es.pdf)

čeština (CS) (164.71 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/cs/documents/overview/braftovi-epar-medicine-overview_cs.pdf)

dansk (DA) (139.12 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/da/documents/overview/braftovi-epar-medicine-overview_da.pdf)

Deutsch (DE) (142.83 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/de/documents/overview/braftovi-epar-medicine-overview_de.pdf)

eesti keel (ET) (134.93 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/et/documents/overview/braftovi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (166.09 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/el/documents/overview/braftovi-epar-medicine-overview_el.pdf)

français (FR) (139.21 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/fr/documents/overview/braftovi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (162.37 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/hr/documents/overview/braftovi-epar-medicine-overview_hr.pdf)

italiano (IT) (136.63 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/it/documents/overview/braftovi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (168.49 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/lv/documents/overview/braftovi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (160.54 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/lt/documents/overview/braftovi-epar-medicine-overview_lt.pdf)

magyar (HU) (163.32 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/hu/documents/overview/braftovi-epar-medicine-overview_hu.pdf)

Malti (MT) (163.19 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/mt/documents/overview/braftovi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (140.58 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/nl/documents/overview/braftovi-epar-medicine-overview_nl.pdf)

polski (PL) (165.29 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/pl/documents/overview/braftovi-epar-medicine-overview_pl.pdf)

português (PT) (138.73 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/pt/documents/overview/braftovi-epar-medicine-overview_pt.pdf)

română (RO) (159.43 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/ro/documents/overview/braftovi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (162.44 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/sk/documents/overview/braftovi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (161.81 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/sl/documents/overview/braftovi-epar-medicine-overview_sl.pdf)

Suomi (FI) (134.85 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/fi/documents/overview/braftovi-epar-medicine-overview_fi.pdf)

svenska (SV) (136.41 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

23/09/2024

[View](/sv/documents/overview/braftovi-epar-medicine-overview_sv.pdf)

Braftovi : EPAR - Risk management plan

English (EN) (1.68 MB - PDF)

**First published:** 12/10/2018

**Last updated:** 05/09/2024

[View](/en/documents/rmp/braftovi-epar-risk-management-plan_en.pdf)

## Product information

Braftovi : EPAR - Product information

English (EN) (916.38 KB - PDF)

**First published:** 12/10/2018

**Last updated:** 05/11/2025

[View](/en/documents/product-information/braftovi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-751)

български (BG) (1.14 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/bg/documents/product-information/braftovi-epar-product-information_bg.pdf)

español (ES) (826.36 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/es/documents/product-information/braftovi-epar-product-information_es.pdf)

čeština (CS) (899.13 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/cs/documents/product-information/braftovi-epar-product-information_cs.pdf)

dansk (DA) (993.57 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/da/documents/product-information/braftovi-epar-product-information_da.pdf)

Deutsch (DE) (984.49 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/de/documents/product-information/braftovi-epar-product-information_de.pdf)

eesti keel (ET) (910.28 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/et/documents/product-information/braftovi-epar-product-information_et.pdf)

ελληνικά (EL) (1.03 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/el/documents/product-information/braftovi-epar-product-information_el.pdf)

français (FR) (956.78 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/fr/documents/product-information/braftovi-epar-product-information_fr.pdf)

hrvatski (HR) (1.02 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/hr/documents/product-information/braftovi-epar-product-information_hr.pdf)

íslenska (IS) (1.05 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/is/documents/product-information/braftovi-epar-product-information_is.pdf)

italiano (IT) (912.7 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/it/documents/product-information/braftovi-epar-product-information_it.pdf)

latviešu valoda (LV) (992.51 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/lv/documents/product-information/braftovi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (942.6 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/lt/documents/product-information/braftovi-epar-product-information_lt.pdf)

magyar (HU) (1 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/hu/documents/product-information/braftovi-epar-product-information_hu.pdf)

Malti (MT) (1.04 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/mt/documents/product-information/braftovi-epar-product-information_mt.pdf)

Nederlands (NL) (1.06 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/nl/documents/product-information/braftovi-epar-product-information_nl.pdf)

norsk (NO) (1.03 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/no/documents/product-information/braftovi-epar-product-information_no.pdf)

polski (PL) (1.11 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/pl/documents/product-information/braftovi-epar-product-information_pl.pdf)

português (PT) (975.37 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/pt/documents/product-information/braftovi-epar-product-information_pt.pdf)

română (RO) (1.05 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/ro/documents/product-information/braftovi-epar-product-information_ro.pdf)

slovenčina (SK) (1.15 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/sk/documents/product-information/braftovi-epar-product-information_sk.pdf)

slovenščina (SL) (1.03 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/sl/documents/product-information/braftovi-epar-product-information_sl.pdf)

Suomi (FI) (759.07 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/fi/documents/product-information/braftovi-epar-product-information_fi.pdf)

svenska (SV) (1019.96 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

05/11/2025

[View](/sv/documents/product-information/braftovi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000241083 18/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Braftovi : All authorised presentations

English (EN) (48.7 KB - PDF)

**First published:** 12/10/2018

**Last updated:** 01/03/2021

[View](/en/documents/all-authorised-presentations/braftovi-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-898)

български (BG) (114.63 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/bg/documents/all-authorised-presentations/braftovi-all-authorised-presentations_bg.pdf)

español (ES) (47.05 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/es/documents/all-authorised-presentations/braftovi-all-authorised-presentations_es.pdf)

čeština (CS) (53.96 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/cs/documents/all-authorised-presentations/braftovi-all-authorised-presentations_cs.pdf)

dansk (DA) (49.3 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/da/documents/all-authorised-presentations/braftovi-all-authorised-presentations_da.pdf)

Deutsch (DE) (52.5 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/de/documents/all-authorised-presentations/braftovi-all-authorised-presentations_de.pdf)

eesti keel (ET) (124.64 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/et/documents/all-authorised-presentations/braftovi-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.49 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/el/documents/all-authorised-presentations/braftovi-all-authorised-presentations_el.pdf)

français (FR) (46.76 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/fr/documents/all-authorised-presentations/braftovi-all-authorised-presentations_fr.pdf)

hrvatski (HR) (108.65 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/hr/documents/all-authorised-presentations/braftovi-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.45 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/is/documents/all-authorised-presentations/braftovi-all-authorised-presentations_is.pdf)

italiano (IT) (48.1 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/it/documents/all-authorised-presentations/braftovi-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (68.86 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/lv/documents/all-authorised-presentations/braftovi-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (99.54 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/lt/documents/all-authorised-presentations/braftovi-all-authorised-presentations_lt.pdf)

magyar (HU) (99.57 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/hu/documents/all-authorised-presentations/braftovi-all-authorised-presentations_hu.pdf)

Malti (MT) (64.07 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/mt/documents/all-authorised-presentations/braftovi-all-authorised-presentations_mt.pdf)

Nederlands (NL) (48.51 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/nl/documents/all-authorised-presentations/braftovi-all-authorised-presentations_nl.pdf)

norsk (NO) (48.84 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/no/documents/all-authorised-presentations/braftovi-all-authorised-presentations_no.pdf)

polski (PL) (67.83 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/pl/documents/all-authorised-presentations/braftovi-all-authorised-presentations_pl.pdf)

português (PT) (48.12 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/pt/documents/all-authorised-presentations/braftovi-all-authorised-presentations_pt.pdf)

română (RO) (59.79 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/ro/documents/all-authorised-presentations/braftovi-all-authorised-presentations_ro.pdf)

slovenčina (SK) (65.04 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/sk/documents/all-authorised-presentations/braftovi-all-authorised-presentations_sk.pdf)

slovenščina (SL) (59.29 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/sl/documents/all-authorised-presentations/braftovi-all-authorised-presentations_sl.pdf)

Suomi (FI) (48.23 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/fi/documents/all-authorised-presentations/braftovi-all-authorised-presentations_fi.pdf)

svenska (SV) (47.33 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

01/03/2021

[View](/sv/documents/all-authorised-presentations/braftovi-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Braftovi Active substance Encorafenib International non-proprietary name (INN) or common name encorafenib Therapeutic area (MeSH)

- Melanoma
- Colorectal Neoplasms

Anatomical therapeutic chemical (ATC) code L01EC03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Melanoma Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Colorectal cancer (CRC) Encorafenib in combination with cetuximab is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC)  with a BRAF V600E mutation, who have received prior systemic therapy. Non-small cell lung cancer (NSCLC) Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.

## Authorisation details

EMA product number EMEA/H/C/004580 Marketing authorisation holder

Pierre Fabre Medicament

Les Cauquillous 81500 - Lavaur France

Opinion adopted 26/07/2018 Marketing authorisation issued 19/09/2018 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Braftovi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (167.56 KB - PDF)

**First published:** 09/07/2025

**Last updated:** 05/11/2025

[View](/en/documents/procedural-steps-after/braftovi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Braftovi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (220.97 KB - PDF)

**First published:** 30/11/2018

**Last updated:** 09/07/2025

[View](/en/documents/procedural-steps-after/braftovi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Braftovi : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

Reference Number: EMADOC-1700519818-2438413

English (EN) (144.12 KB - PDF)

**First published:** 05/11/2025

[View](/en/documents/pip-compliance/braftovi-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

Braftovi-H-C-4280-WS-2538 EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/372317/2024

English (EN) (3.2 MB - PDF)

**First published:** 05/09/2024

[View](/en/documents/variation-report/braftovi-h-c-4280-ws-2538-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Braftovi (WS-2538)

Adopted

Reference Number: EMA/CHMP/323249/2024

English (EN) (156.41 KB - PDF)

**First published:** 26/07/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-braftovi-ws-2538_en.pdf)

Braftovi-H-C-PSUSA-00010719-202306 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/126479/2024

English (EN) (127.12 KB - PDF)

**First published:** 09/04/2024

[View](/en/documents/scientific-conclusion/braftovi-h-c-psusa-00010719-202306-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Braftovi-H-C-4280-WS-1695 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/271532/2020

English (EN) (15.23 MB - PDF)

**First published:** 16/06/2020

[View](/en/documents/variation-report/braftovi-h-c-4280-ws-1695-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Braftovi (WS-1695)

Adopted

Reference Number: EMA/CHMP/217942/2020

English (EN) (133.78 KB - PDF)

**First published:** 30/04/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-braftovi-ws-1695_en.pdf)

## Initial marketing authorisation documents

Braftovi : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/554696/2018

English (EN) (5.97 MB - PDF)

**First published:** 12/10/2018

[View](/en/documents/assessment-report/braftovi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Braftovi

Adopted

Reference Number: EMA/CHMP/476007/2018

English (EN) (69.09 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-braftovi_en.pdf)

#### News on Braftovi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020) 30/04/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

#### More information on Braftovi

- [EMEA-001588-PIP01-13-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001588-pip01-13-m03)
- [EMEA-001588-PIP03-18 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001588-pip03-18)
- [EMEA-001588-PIP04-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001588-pip04-23)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/11/2025

## Share this page

[Back to top](#main-content)